Zoonotic influenza - Annual Epidemiological Report for 2015
No human cases of avian influenza were reported in the EU/EEA.
Communicable disease threats report, 29 October-4 November 2017, week 44
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 October-4 November 2017 and includes updates on chikungunya, Legionnaires' disease, malaria, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza A(H7N9), plague, poliomyelitis, seasonal influenza and West Nile virus.
Influenza virus characterisation, Summary Europe, September 2017
In the course of the 2016–17 influenza season, over 146 000 influenza detections across the WHO Europe Region have been reported.
Influenza surveillance for the 2017-2018 season is starting
ECDC monitors and reports on influenza transmission and virus circulation in Europe on a weekly basis throughout the flu season, in collaboration with WHO Regional Office for Europe, in the report Flu News Europe.
ECDC/EFSA joint report: Avian inﬂuenza overview October 2016–August 2017
The A(H5N8) highly pathogenic avian inﬂuenza (HPAI) epidemic occurred in 29 European countries in 2016/2017 and has been the largest ever recorded in the EU in terms of number of poultry outbreaks, geographical extent and number of dead wild birds.
Communicable Disease Threat Report, 2 - 9 September 2017, week 36
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 27 August - 2 September 2017 and includes updates on measles, MERS, West Nile fever and Chikungunya.
Influenza virus characterisation, Summary Europe, July 2017
In the course of the 2016–17 influenza season, nearly 146 000 influenza detections have been reported across the WHO European Region.
Influenza virus characterisation, Summary Europe, June 2017
In the course of the 2016–2017 influenza season, nearly 146 000 influenza detections across the EU/EAA region have been reported.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.